5F9-Rituxan Combo Eliminates Tumors in One-third of DLBCL, Follicular Lymphoma Patients
News
A combination of Forty Seven‘s macrophage checkpoint inhibitor Hu5F9-G4 and Rituxan (rituximab) is safe and completely eliminated tumors in one-third of non-Hodgkin’s lymphoma patients included in a Phase 1b trial. The trial, ... Read more